Yongxian Hu

29PUBLICATIONS
70CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsHaematological tumoursPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (29)

|Sep 28, 2026
Comparative clinical outcomes and single-cell profiling of CD19 CAR-T versus blinatumomab for relapsed/refractory B-ALL.

|Sep 15, 2026
Targeting BLVRB Overcomes Immunosuppression and Potentiates Immunotherapy in Monocytic Acute Myeloid Leukemia.

|Jul 22, 2026
The Gut Microbiome Drives Endogenous T-cell Activation Following CAR T-cell Therapy.

|Jul 08, 2026
Genetic Mutation and Epigenetic Silencing Drive Antigen-Negative Relapse in CD7 CAR T-Treated T-cell Lymphoid Malignancies.

|Jul 03, 2026
CD7 chimeric antigen receptor T cells in patients with relapsed or refractory CD7-positive acute myeloid leukemia.

|May 15, 2026
CD19/BCMA-Targeted Chimeric Antigen Receptor-T Cell Therapy for Anti-HLA Antibody Sensitisation in Patients With Acute Leukaemia: A Pilot Clinical Study.

Pageof 5

Frequent Collaborators

21 joint publications

He Huang

5 joint publications

Dongrui Wang

4 joint publications

Alex Hongsheng Chang

3 joint publications

Houli Zhao